-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Rocket Pharmaceuticals, Raises Price Target to $9

Benzinga·03/30/2026 13:39:53
Listen to the news
B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and raises the price target from $8 to $9.